CSL: Result 2015

CSL's growth was slow in 2015, but management has high hopes for its new influenza business.

Blood products maker CSL has reported a decent full year result, with revenue increasing 2% to US$5.5bn compared to a year earlier, or 7% after removing the effect of currency fluctuations. At constant currency and excluding one-off acquisition costs for its new influenza unit (see below), net profit increased 10% to US$1.4bn while earnings per share increased 13% to $2.91 due to the ongoing share buyback program.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles